Alebund Pharmaceuticals, recognized for its pioneering work in developing innovative treatments for kidney disease, has announced the closure of its Pre-C round of financing, securing nearly RMB 200 million. This significant financial boost is earmarked for advancing the company's R&D pipeline, which is currently focused on three Class I innovative drugs undergoing Phase I, II, and III clinical developments.
With a team rich in renal R&D experience, Alebund is committed to enhancing its portfolio to benefit patients globally. The company anticipates that 1-2 in-house developed products will enter clinical testing by 2024, marking a significant milestone in its mission to address kidney disease through innovative medical solutions.
